{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alisertib+%28MLN8237%29", "query": { "intervention": "Alisertib (MLN8237)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 58, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alisertib+%28MLN8237%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T07:48:01.219Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02530619", "title": "Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Megakaryoblastic Leukemia", "Myelofibrosis", "Primary Myelofibrosis" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2015-10-09", "completion_date": "2022-05", "has_results": true, "last_update_posted_date": "2021-05-26", "last_synced_at": "2026-10-02T07:48:01.219Z", "location_count": 3, "location_summary": "Miami, Florida • Chicago, Illinois • Rochester, Minnesota", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02530619" }, { "nct_id": "NCT01091428", "title": "Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Carcinoma", "Fallopian Tube Cancer", "Peritoneal Cancer", "Breast Carcinoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 191, "start_date": "2010-04-16", "completion_date": "2017-07-19", "has_results": true, "last_update_posted_date": "2018-06-04", "last_synced_at": "2026-10-02T07:48:01.219Z", "location_count": 4, "location_summary": "The Bronx, New York • Philadelphia, Pennsylvania • Houston, Texas + 1 more", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01091428" }, { "nct_id": "NCT01637961", "title": "Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Uterine Corpus Sarcoma", "Uterine Corpus Leiomyosarcoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 23, "start_date": "2012-08", "completion_date": "2017-02-11", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-10-02T07:48:01.219Z", "location_count": 50, "location_summary": "Hartford, Connecticut • New Britain, Connecticut • Orlando, Florida + 37 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01637961" }, { "nct_id": "NCT01482962", "title": "Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Peripheral T-Cell Lymphoma", "Refractory Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 271, "start_date": "2012-06-11", "completion_date": "2017-12-18", "has_results": true, "last_update_posted_date": "2018-07-31", "last_synced_at": "2026-10-02T07:48:01.219Z", "location_count": 24, "location_summary": "Birmingham, Alabama • La Jolla, California • Orlando, Florida + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482962" }, { "nct_id": "NCT02700022", "title": "A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-cell Lymphoma", "Follicular Lymphoma", "Burkitt Lymphoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2016-10", "completion_date": "2017-08-18", "has_results": false, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-10-02T07:48:01.219Z", "location_count": 2, "location_summary": "Duarte, California • Chapel Hills, North Carolina", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chapel Hills", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02700022" }, { "nct_id": "NCT02327169", "title": "A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Nonhematologic Malignancies" ], "interventions": [ { "name": "MLN2480", "type": "DRUG" }, { "name": "MLN0128", "type": "DRUG" }, { "name": "Alisertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2015-01-14", "completion_date": "2018-07-02", "has_results": true, "last_update_posted_date": "2020-02-25", "last_synced_at": "2026-10-02T07:48:01.219Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02327169" }, { "nct_id": "NCT01653028", "title": "Alisertib in Treating Patients With Advanced or Metastatic Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myxofibrosarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Leiomyosarcoma", "Recurrent Liposarcoma", "Recurrent Malignant Peripheral Nerve Sheath Tumor", "Recurrent Undifferentiated Pleomorphic Sarcoma", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2012-08-22", "completion_date": null, "has_results": true, "last_update_posted_date": "2017-11-30", "last_synced_at": "2026-10-02T07:48:01.219Z", "location_count": 235, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 153 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01653028" }, { "nct_id": "NCT02219789", "title": "Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor Positive", "Progesterone Receptor Positive", "Recurrent Breast Carcinoma", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2014-12-05", "completion_date": "2018-10-01", "has_results": false, "last_update_posted_date": "2018-10-03", "last_synced_at": "2026-10-02T07:48:01.219Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02219789" }, { "nct_id": "NCT02860000", "title": "Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Status", "HER2/Neu Negative", "Invasive Breast Carcinoma", "Postmenopausal", "Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 96, "start_date": "2017-07-06", "completion_date": "2025-02-14", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-02T07:48:01.219Z", "location_count": 8, "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02860000" }, { "nct_id": "NCT01639911", "title": "Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Neoplasm of Breast", "CNS Malignancy", "Malignant Neoplasm of Gastrointestinal Tract", "Genitourinary Neoplasms Malignancy and Gender Unspecified", "Head and Neck Neoplasms", "Melanoma", "Malignant Neoplasm of Thorax" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2013-08-14", "completion_date": "2016-07-28", "has_results": false, "last_update_posted_date": "2019-07-22", "last_synced_at": "2026-10-02T07:48:01.219Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01639911" } ] }